seri
dion
construct
util
cu
catalyz
azidealkyn
cycloaddit
cuaac
method
biolog
signific
novel
synthes
quinazolin
highlight
evalu
vitro
antivir
activ
wherein
sever
compound
exhibit
excel
activ
specif
vaccinia
adenoviru
especi
display
potent
inhibitori
activ
vaccinia
ec
valu
lm
fold
refer
drug
cidofovir
ec
lm
potent
compound
ec
valu
lm
prove
lower
refer
drug
preliminari
structureact
relationship
also
discuss
best
knowledg
data
present
literatur
antivir
activ
dion
dnavirus
thu
find
warrant
investig
librari
expans
compound
refin
novel
class
antivir
agent
poxvirusassoci
diseas
major
threat
human
health
smallpox
highli
transmiss
infecti
diseas
high
morbid
mortal
danger
human
pathogen
poxvirus
group
although
smallpox
declar
erad
world
health
organ
intens
immun
campaign
vaccinia
viru
vaccin
global
stock
varv
kept
two
whoapprov
laboratori
us
center
diseas
control
prevent
cdc
atlanta
russian
state
research
center
virolog
biotechnolog
novosibirsk
fact
vaccinia
viru
vaccin
substanti
side
effect
vaccin
program
termin
sinc
last
centuri
led
human
popul
today
suscept
smallpox
disast
addit
emerg
zoonot
poxviru
infect
monkeypox
viru
us
western
africa
human
popul
aggrav
peopl
panic
reason
special
attent
paid
establish
effici
safe
therapi
deal
poxviru
infect
spite
number
potenti
antipoxvir
agent
report
recent
approv
drug
us
food
drug
administr
fda
prevent
treatment
smallpox
infect
avail
market
current
cidofovir
cdv
potent
select
antidna
viru
agent
inhibit
viral
dna
replic
fig
broadspectrum
activ
approv
treatment
smallpox
viru
low
oral
bioavail
cdv
potenti
nephrotox
accompani
intraven
administr
limit
clinic
applic
cdv
recent
lipophil
prodrug
cdv
hexadecyloxypropyl
ester
hdpcdv
demonstr
improv
bioavail
equival
effect
orthopoxviru
infect
phase
iii
clinic
studi
current
moreov
tecovirimat
oral
bioavail
compound
target
protein
viru
inhibit
growth
multipl
orthopoxvirus
signific
antivir
activ
variou
poxviru
diseas
anim
model
demonstr
favor
safeti
toler
pharmacokinet
phase
clinic
trial
tecovirimat
receiv
orphan
drug
design
fasttrack
statu
us
fda
hope
approv
prevent
treatment
smallpox
infect
adenovirus
adv
doublestrand
dna
virus
nm
size
nonenvelop
icosahedr
capsid
genom
kb
adv
compris
human
ad
serotyp
identifi
classifi
six
speci
af
term
biolog
physiochem
genet
properti
adv
opportunist
pathogen
associ
wide
varieti
sever
clinic
symptom
healthi
individu
respiratori
ill
renal
diseas
gastroenter
hemorrhag
cystiti
howev
gener
consid
highli
pathogen
virus
reason
adenoviru
infect
often
selflimit
immunocompet
individu
adenoviru
infect
might
led
sever
lifethreaten
diseas
multipl
organ
failur
immunocompromis
individu
last
two
decad
number
adenoviru
serotyp
larg
speci
b
c
isol
immunocompromis
patient
success
speci
serotyp
detail
studi
adenoviru
far
often
associ
respiratori
ill
lethal
outcom
occasion
current
avail
drug
treatment
adv
infect
cidofovir
prove
promis
antiadenovir
agent
current
use
clinic
set
outcom
hematopoiet
stem
cell
recipi
found
poor
adenoviru
infect
therefor
compel
need
discoveri
new
antivir
drug
vaccinia
adenoviru
possess
improv
safeti
properti
oral
bioavail
past
decad
serendipit
highthroughput
screen
ht
campaign
heterocycl
compound
collect
continu
remain
major
paradigm
antivir
hit
lead
discoveri
due
chemic
biolog
import
hydroxi
iso
dion
analogu
attract
privileg
structur
antivir
medicin
chemistri
recent
dion
deriv
report
miscellan
inhibitor
target
bridg
dinuclear
metalloenzym
hiv
rnase
h
integras
dual
inhibitor
hiv
rnase
h
activesit
inhibitor
well
hepat
c
viru
hcv
polymeras
inhibitor
fig
suggest
dival
metal
ion
chelat
could
use
inhibitor
scaffold
broad
rang
biolog
activ
via
variou
modif
evolv
concept
drug
reposit
privileg
structureguid
scaffold
refin
effect
strategi
exploit
undescrib
bioactivit
make
full
use
readili
derivat
scaffold
wellestablish
synthet
method
context
view
fact
discov
complet
new
antivaccinia
adenoviru
agent
novel
skeleton
uniqu
mode
action
rel
small
librari
dion
compound
gener
formula
scheme
construct
via
copper
catalyz
azidealkyn
cycloaddit
cuaac
reaction
biolog
signific
novel
synthes
quinazolin
highlight
evalu
cell
culturebas
antivir
highthroughput
screen
ht
assay
broad
panel
dna
virus
retrovirus
sever
rna
virus
librari
one
compound
construct
follow
gener
synthet
rout
straightforward
depict
scheme
start
materi
firstli
react
benzyl
bromid
obtain
benzyloxi
treat
hydrochlor
acid
acet
acid
via
acidul
reaction
form
key
intermedi
obenzylhydroxylamin
hydrochlorid
meanwhil
commerci
avail
materi
acid
obtain
ring
closur
carbonyldimidazol
cdi
condit
sodium
hydroxid
heterocycl
scaffold
alkyl
iodomethan
iodoethan
dmf
afford
n
product
n
ethyl
product
respect
key
alkyn
build
block
prepar
via
sonogashira
crosscoupl
reaction
trimethylsilylremov
reaction
success
copper
catalyz
click
reaction
cuaac
alkyn
key
intermedi
differ
azido
substitu
group
gener
correspond
key
intermedi
deprotect
basic
condit
afford
two
seri
target
compound
dion
structur
determin
h
nmr
c
nmr
ms
esi
spectra
notabl
h
nmr
spectrum
show
singlet
correspond
triazolyl
proton
c
nmr
spectrum
show
peak
correspond
ch
qc
characterist
triazol
core
unit
newli
synthes
dion
perform
evalu
antivir
activ
broad
panel
dna
viru
includ
herp
simplex
ko
herp
simplex
g
herp
simplex
tkko
acvr
vaccinia
viru
adeno
evalu
infect
human
embryon
lung
fibroblast
hel
cell
addit
compound
also
examin
retrovirus
ie
human
immunodefici
viru
type
type
sever
rna
virus
ie
human
coronaviru
influenza
viru
result
express
ec
mcc
minimum
cytotox
concentr
tabl
shown
tabl
hdpcdv
vaccinia
adenoviru
studi
help
relat
structur
characterist
complex
antivir
activ
preliminari
investig
structureact
relationship
sar
reveal
natur
n
r
substitu
aryl
group
connect
triazol
influenc
antivir
activ
remark
instanc
result
reveal
antivir
activ
n
ethyl
substitut
analogu
potent
correspond
n
methyl
substitut
counterpart
ec
especi
n
ethyl
substitut
analogu
show
favor
activ
adenoviru
nearli
compound
lost
activ
compound
n
methyl
substitut
counterpart
except
compound
introduct
electronwithdraw
group
para
substitu
aryl
remark
improv
antivaccinia
activ
cn
f
ch
contrari
strong
electronwithdraw
group
result
compound
lost
adenoviru
activ
compound
electrondraw
group
exhibit
potent
antivir
activ
adenoviru
compar
compound
compound
fluorin
substitut
meta
para
posit
aryl
simultan
display
potent
inhibitori
activ
toward
vaccinia
ec
lm
adenoviru
compound
ortho
meta
substitut
show
moder
inhibitori
activ
ec
lm
ec
lm
parasubstitut
counterpart
inact
ec
lm
moreov
chang
pattern
substitut
aryl
disubstitut
result
reduc
activ
ec
lm
even
complet
lost
inhibitori
activ
ec
lm
conclus
seri
novel
dion
synthes
use
cuaac
reaction
firstli
identifi
potent
specif
vaccinia
adenoviru
inhibitor
vitro
among
demonstr
potent
vaccinia
adenoviru
inhibitori
activ
respect
promis
compound
explor
drug
candid
antipoxviru
adenoviru
therapi
preliminari
sar
discuss
hope
provid
help
guidanc
design
nextgener
quinolinon
analogu
obvious
mechan
action
precis
viral
target
dion
deriv
present
remain
identifi
consequ
detail
studi
elabor
dion
investig
prospect
mechan
action
current
underway
lab
would
disclos
due
cours
financi
support
nation
natur
scienc
